ReviewIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2010
Nonalcoholic fatty liver disease in India - a lot done, yet more required!
Review in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 114 citations in OpenAlex.
- Changes of the Fatty Acid Profile in Erythrocyte Membranes of Patients following 6-Month Dietary Intervention Aimed at the Regression of Nonalcoholic Fatty Liver Disease (NAFLD).Canadian journal of gastroenterology & hepatology · 2018Trial
- The Impact of Sira Vedha (Phlebotomy) at the Right Elbow Joint in the Treatment of Non-Alcoholic Fatty Liver Disease - A Research Report.Journal of pharmacy & bioallied sciences · 2024Article
- Aging, ROS, and cellular senescence: a trilogy in the progression of liver fibrosis.Biogerontology · 2024Review
- Article
- Article
- Article
- Association of GCKR and MBOAT7 genetic polymorphisms with non-alcoholic fatty liver disease.Clinical and experimental hepatology · 2024Article
- Diagnostic performance of non-invasive liver fibrosis risk scores in biopsy-proven non-alcoholic fatty liver disease patients in India.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Article
- Review
- The association between obesity with serum levels of liver enzymes, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and gamma-glutamyl transferase in adult women.Endocrinology, diabetes & metabolism · 2022Article
- Factors influencing circulating microRNAs as biomarkers for liver diseases.Molecular biology reports · 2022Review
- Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls.TouchREVIEWS in endocrinology · 2021Review
- Number needed to screen to prevent progression of liver fibrosis to cirrhosis at primary health centers: An experience from Delhi.Journal of family medicine and primary care · 2021Article
- Cellular Mechanisms of Liver Fibrosis.Frontiers in pharmacology · 2021Review
- Prevalence and determinants of hepatopulmonary syndrome in decompensated chronic liver disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020Observational
- Non-alcoholic fatty liver and cancer.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020Article
- Treatment of non-alcoholic fatty liver disease - Current perspectives.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020Review
- Metabolic syndrome is not uncommon among lean non-alcoholic fatty liver disease patients as compared with those with obesity.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020Article
- Computed tomography-based evaluation of segmental variation of liver density and its implications.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020Article
- Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is emerging as an important cause of liver disease in India. Epidemiological studies suggest prevalence of NAFLD in around 9% to 32% of general population in India with higher prevalence in those with overweight or obesity and those with diabetes or prediabetes. Clinicopathological studies show that NAFLD is an important cause of unexplained rise in hepatic transaminases, cryptogenic cirrhosis and cryptogenic hepatocellular carcinoma in Indian patients. There is high prevalence of insulin resistance and nearly half of Indian patients with NAFLD have evidence of full-blown metabolic syndrome. Though oxidative stress is involved in the pathogenesis of NAFLD/nonalcoholic steatohepatitis, serum or liver iron and HFE gene mutations appear not to play a role in the pathogenesis of NAFLD in Indian patients. Imaging modalities are not useful in differentiating simple steatosis from NASH and liver biopsy may be useful in those with risk factors for significant liver disease. Pilot studies on treatment strategies have shown that weight reduction and exercise, ursodeoxycholic acid, metformin, vitamin E and pentoxyfylline are effective in normalizing transaminases and or in improving hepatic steatosis and inflammation in Indian patients with NAFLD. Randomized controlled treatment trials involving large number of patients with histological end point are required to assess the efficacy of different modalities. In conclusion, a lot has been done, yet more is required to understand various aspects of NAFLD in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.